Abstract:
Compounds of formula (I): wherein: X is a group of formula (B): and R1, R2, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, are also described.
Abstract:
Spun-bond nonwoven material made of continuous filaments or fibers, whereby the continuous filaments or fibers are multi-component filaments, in particular bi-component filaments, with a low-melting component on the outer surface. The spun-bond nonwoven material is thermally bonded in a calender. The spun-bond nonwoven material has a mass per unit area of more than 40 g/m2.
Abstract translation:由连续长丝或纤维制成的纺粘非织造材料,其中连续长丝或纤维是多组分长丝,特别是双组分长丝,外表面具有低熔点成分。 纺粘非织造材料在压延机中热粘合。 纺粘非织造材料的单位面积质量大于40g / m 2。
Abstract:
A distraction osteogenesis fixture to be anchored in a bone, including a lower anchor, a translational screw, and an upper anchor. At least a portion of the lower anchor is externally threaded. At least a portion of the lower anchor includes an anti-rotational feature. The lower anchor includes an internal passage. At least a portion of the internal passage is threaded. At least a portion of the translational screw is externally threaded such that the translational screw is receivable by the threaded internal passage of the lower anchor. The upper anchor includes an internal passage for receiving a portion of the lower anchor and has an anti-rotational feature for engaging the anti-rotational feature of the lower anchor. The internal passage of the upper anchor includes a surface for engaging the translational screw. At least a portion of the upper anchor is externally threaded.
Abstract:
A power and safety control hub, integrating fault tolerant power disconnect control, software monitoring of disconnect and multi-voltage power distribution and disconnect with non-hazardous power control, EMI filtering and multi-circuit current protection in a single unit, coordinating shutdown of connected mechanical drives, commanding them to come to a controlled stop before safety power is disconnected. The hub may also integrates segmented hazardous power control and automatically discharge energy sources within connected mechanical drives at the time of safety power disconnect of hazardous power. The hub may also include internal self-protection that automatically forces a control safety power disconnect (after warning the host) if the unit should approach its maximum operating temperature, or if a cooling fan stops.
Abstract:
This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
Abstract:
This invention relates to novel compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
Abstract:
This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
Abstract:
The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor: wherein: R1, R2, R3 and X1-X6 are as defined within or a pharmaceutically acceptable salt, prodrug or solvate thereof, is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
Abstract:
A method of determining at least the concentration of a component from the intensity of electromagnetic waves with at least two selected wavelengths which are reflected by human tissue or transmitted through human tissue comprises firstly the step of converting the intensities of the received electromagnetic signals into at least one first and one second time-dependent electric signal. Then a time-discrete transformation of the first and of the second electric signal into the frequency domain is performed to determine first and second spectral values of the first and of the second signal. Complex combinatorial values are formed from said first and second spectral values and physiologically relevant combinatorial values are selected by evaluating the complex combinatorial values according to given criteria for the physiological relevance thereof. Finally, the concentration of the component is calculated by using the selected combinatorial values or by using the frequencywise-associated spectral values.